Quantcast
Last updated on April 24, 2014 at 13:15 EDT

Latest Keystone Heart Ltd. Stories

2013-09-09 04:21:21

CAESAREA, Israel, September 9, 2013 /PRNewswire/ -- - CE Marking for the TriGuard(TM) device, devised to minimize the risk of brain damage during TAVR, enables commencement of commercial use - Recent data demonstrates considerable reduction of new brain lesion volume during protected TAVR procedures performed with the TriGuard medical device Keystone Heart, a leader in the development of cerebral protection devices for...

2013-05-22 16:25:21

PARIS and CAESAREA, Israel, May 22, 2013 /PRNewswire/ -- - New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart's TriGuard [http://www.keystoneheart.com/products ](TM) Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures when compared to historical data. - Keystone Heart Scientific Advisory Board announces consensus on the...

2012-04-25 10:25:01

HERZLIYA PITUACH, Israel, April 25, 2012 /PRNewswire/ -- SMT Research & Development, Ltd. ("SMT") today announced the addition of three key executives to its management team, including a new CEO, CFO and Chief Medical Officer, plus two additions to its board of directors. The Company also announced that the Company's shareholders and board of directors have approved the Company's name change to Keystone Heart Ltd. Keystone Heart's new President and Chief Executive Officer, Mr. Shuki...